Use of cyclosporin in the treatment of steroid resistant post-keratoplasty atopic sclerokeratitis.
OBJECTIVE
To demonstrate that oral cyclosporin is successful in the management of steroid refractory post-keratoplasty atopic sclerokeratitis (PKAS).


METHODS
Series of three patients.


RESULTS
The patients developed PKAS between 2 and 11 days after surgery. All cases failed to respond to oral prednisolone 60-80 mg daily for 10-30 days but resolved with the addition of systemic cyclosporin 5.0-7.5 mg/kg/day. There have been no relapses following withdrawal of therapy after 3-18 months.


CONCLUSIONS
PKAS is an uncommon, but severe, complication of corneal graft surgery and often responds to oral prednisolone treatment. Oral cyclosporin results in rapid resolution of PKAS in steroid unresponsive cases.
Daniell
M D
MD
Corneal Service, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
Dart
J K
JK
Lightman
S
S
D000328:Adult; D016572:Cyclosporine / Q000627:therapeutic use*; D004351:Drug Resistance; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007634:Keratitis / Q000188:drug therapy*; D015948:Keratoplasty, Penetrating; D008297:Male; D011183:Postoperative Complications / Q000188:drug therapy; D015423:Scleritis / Q000188:drug therapy*
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016572:Cyclosporine